BioLineRx (BLRX) Free Cash Flow (2013 - 2025)

BioLineRx's Free Cash Flow history runs 13 years deep, the most recent figure standing at -$3.2 million for Q4 2025.

• On a quarterly basis, Free Cash Flow rose 62.86% year-over-year to -$3.2 million in Q4 2025; TTM through Dec 2025 was -$8.1 million, a 81.57% increase from a year earlier, with the FY2025 full-year figure at -$8.0 million, up 81.63% from the prior year.
• Free Cash Flow retreated to -$3.2 million in Q4 2025 per BLRX's latest filing, from -$2.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $5.0 million in Q4 2023 and bottomed at -$14.1 million in Q1 2024.
• The 5-year median for Free Cash Flow is -$6.2 million (2021), against an average of -$6.2 million.
• Across the five-year window, Free Cash Flow soared 189.0% in 2023 and plunged 272.08% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$5.4 million in 2021, then decreased by 3.4% to -$5.6 million in 2022, then surged by 189.0% to $5.0 million in 2023, then plunged by 272.08% to -$8.6 million in 2024, then surged by 62.86% to -$3.2 million in 2025.
• Per Business Quant, the three latest BLRX Free Cash Flow figures stand at -$3.2 million (Q4 2025), -$2.1 million (Q3 2025), and -$177000.0 (Q2 2025).